Methotrexate in rheumatoid arthritis: a prospective study in Israeli patients with immunogenetic correlations.
AUTOR(ES)
Tishler, M
RESUMO
In a prospective open study 44 Israeli patients with rheumatoid arthritis were treated with weekly low dose methotrexate (MTX) for up to 36 months. Nine patients withdrew from the study: six because of side effects and three due to inefficacy. One patient died of septicaemia following septic arthritis. Significant improvement, graded by Ritchie articular index, grip strength, physician's global assessment, erythrocyte sedimentation rate (ESR), and platelet counts, was noticed in response to treatment. Seronegative patients had a better clinical response. Transient gastrointestinal symptoms were common and correlated with increases of serum aspartate transaminase (AST). HLA-DR1 and DR7 were significantly associated with increased serum AST concentrations.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1006717Documentos Relacionados
- The cervical spine in patients with psoriatic arthritis: a clinical, radiological and immunogenetic study.
- Mortality and survival in rheumatoid arthritis: a 25 year prospective study of 100 patients.
- Salicylate ototoxicity in patients with rheumatoid arthritis: a controlled study.
- Pauciarticular juvenile rheumatoid arthritis: clinical and immunogenetic aspects.
- Methotrexate-related pulmonary complications in patients with rheumatoid arthritis: cluster of five cases in a period of three months.
